Abstract：
To evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for desmoid tumors (DTs).
A total of 111 patients with histologically proven DTs were included and treated by USgHIFU ablation. Adverse events were continuously evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 until 3 months after treatment. The incidence of non-perfused areas within the treated tumors, non-perfused volume rate (NPVR) and tumor volume reduction were evaluated using contrast-enhanced MRI before and one week and 3 months after the procedure.
The enrolled patients (32 male, 79 female, mean age 29.5 ± 1.0 years) with 145 DTs (118 extra-abdominal, 16 abdominal wall, 11 intra-abdominal; median maximum diameter: 9.6 cm, range: 3-34.5 cm) underwent 188 sessions of HIFU ablation, and the mean number of ablations was 1.7 (range, 1-7) per patient. In majority of cases (143/145 cases, 98.6%), no serious adverse events were observed. There was no significant difference in the incidence of adverse events between patients who received a single treatment and those who received multiple treatments. Non-perfused area was observed within every treated tumor, and the median NPVR was 84.9% (range, 1.9-100%). The tumor volume reduction rate was 36.1 ± 4.2% at 3 months after treatment.
USgHIFU ablation, as a noninvasive and easily repeatable local treatment, is a promising treatment for DTs.
A total of 111 patients with histologically proven DTs were included and treated by USgHIFU ablation. Adverse events were continuously evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 until 3 months after treatment. The incidence of non-perfused areas within the treated tumors, non-perfused volume rate (NPVR) and tumor volume reduction were evaluated using contrast-enhanced MRI before and one week and 3 months after the procedure.
The enrolled patients (32 male, 79 female, mean age 29.5 ± 1.0 years) with 145 DTs (118 extra-abdominal, 16 abdominal wall, 11 intra-abdominal; median maximum diameter: 9.6 cm, range: 3-34.5 cm) underwent 188 sessions of HIFU ablation, and the mean number of ablations was 1.7 (range, 1-7) per patient. In majority of cases (143/145 cases, 98.6%), no serious adverse events were observed. There was no significant difference in the incidence of adverse events between patients who received a single treatment and those who received multiple treatments. Non-perfused area was observed within every treated tumor, and the median NPVR was 84.9% (range, 1.9-100%). The tumor volume reduction rate was 36.1 ± 4.2% at 3 months after treatment.
USgHIFU ablation, as a noninvasive and easily repeatable local treatment, is a promising treatment for DTs.
摘要：
评价超声引导下高强度聚焦超声(USgHIFU)消融治疗韧带样肿瘤(DTs)的安全性和有效性。
共纳入111例经组织学证实的DTs患者，并通过USgHIFU消融治疗。根据不良事件通用术语标准（CTCAE）5.0版连续评估不良事件，直至治疗后3个月。治疗肿瘤内非灌注区域的发生率，术前、术后1周和3个月使用对比增强MRI评估非灌注体积率(NPVR)和肿瘤体积减少.
入选患者（32名男性，79女，平均年龄29.5±1.0岁)，145个DTs(118个腹外，16腹壁，11腹内；中位最大直径：9.6cm，范围：3-34.5厘米）接受了188次HIFU消融，平均消融次数为1.7(范围，1-7）每位患者。在大多数情况下（143/145例，98.6%），未观察到严重不良事件.在接受单一治疗的患者和接受多种治疗的患者之间，不良事件的发生率没有显着差异。在每个治疗的肿瘤中观察到非灌注区域，NPVR中位数为84.9%(范围，1.9-100%）。治疗后3个月肿瘤体积缩小率为36.1±4.2%。
USgHIFU消融,作为一种无创和易于重复的局部治疗，是DTs的一种有希望的治疗方法。
共纳入111例经组织学证实的DTs患者，并通过USgHIFU消融治疗。根据不良事件通用术语标准（CTCAE）5.0版连续评估不良事件，直至治疗后3个月。治疗肿瘤内非灌注区域的发生率，术前、术后1周和3个月使用对比增强MRI评估非灌注体积率(NPVR)和肿瘤体积减少.
入选患者（32名男性，79女，平均年龄29.5±1.0岁)，145个DTs(118个腹外，16腹壁，11腹内；中位最大直径：9.6cm，范围：3-34.5厘米）接受了188次HIFU消融，平均消融次数为1.7(范围，1-7）每位患者。在大多数情况下（143/145例，98.6%），未观察到严重不良事件.在接受单一治疗的患者和接受多种治疗的患者之间，不良事件的发生率没有显着差异。在每个治疗的肿瘤中观察到非灌注区域，NPVR中位数为84.9%(范围，1.9-100%）。治疗后3个月肿瘤体积缩小率为36.1±4.2%。
USgHIFU消融,作为一种无创和易于重复的局部治疗，是DTs的一种有希望的治疗方法。
